For many people with a bleeding disorder, access to care is a considerable daily challenge. The expanded WFH Humanitarian Aid Program aims to address this problem by providing patients—including children—with the support they need to lead normal lives. Thanks to the multi-year factor donations provided by our partners, people with bleeding disorders in the developing world have continued access to treatment for emergency situations, acute bleeds, corrective surgeries, and prophylaxis for young children.
The WFH Humanitarian Aid Program continues to have a real and sustained impact on the bleeding disorders community. Up until 2019, 19,792 patients have received treatment through the Program. Over 73 countries received donations, and nearly 120,000 infusions were given. Other encouraging news coming out of the efforts of the Program include the fact that 1,622 people were put on prophylactic treatment in 2019, of which 475 were under four years of age. Equally encouraging is the fact that 64,722 acute bleeds were treated last year, and 789 surgeries were completed thanks to the availability of donated product. In short, all the major metrics show marked improvements over the 2018 numbers, which were already very positive.
These significant results are a direct result of the donations provided by Sanofi Genzyme and Sobi. Their 5-year Visionary commitment of 500 million international units of clotting factor concentrates treatment products and their substantial financial support for the operational needs of the Program are having an important impact on people with hemophilia (PWH) in developing countries worldwide.